Search Results - "RIXE, O"

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network by Malouf, G.G., Camparo, P., Oudard, S., Schleiermacher, G., Theodore, C., Rustine, A., Dutcher, J., Billemont, B., Rixe, O., Bompas, E., Guillot, A., Boccon-Gibod, L., Couturier, J., Molinié, V., Escudier, B.

“…Xp11 translocation renal cell carcinoma (RCC) is an RCC subtype affecting 15% of RCC patients <45 years. We analyzed the benefit of targeted therapy [vascular…”
Get full text

Hypertension as a predictive factor of Sunitinib activity by Rixe, O, Billemont, B, Izzedine, H

Get full text

Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib by Beuselinck, B., Oudard, S., Rixe, O., Wolter, P., Blesius, A., Ayllon, J., Elaidi, R., Schöffski, P., Barrascout, E., Morel, A., Escudier, B., Lang, H., Zucman-Rossi, J., Medioni, J.

“…The aim of our study was to determine whether the presence of bone metastases affects outcomes in patients with metastatic clear-cell renal cell carcinoma…”
Get full text

Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives by Spano, J. P., Fagard, R., Soria, J.-C., Rixe, O., Khayat, D., Milano, G.

“…Epidermal growth factor receptor (EGFR) belongs to a family of receptors known as the ErbB family (ErbB tyrosine kinase receptors) which comprises four…”
Get full text

Hypertension as a predictive factor of Sunitinib activity by Rixe, O, Billemont, B, Izzedine, H

Get full text

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib by Billemont, B, Medioni, J, Taillade, L, Helley, D, Meric, J B, Rixe, O, Oudard, S

“…Sunitinib, a multitargeted tyrosine-kinase inhibitor, extends survival of patients with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal…”
Get full text

Thrombotic microangiopathy and anti-VEGF agents by Izzedine, Hassane, Brocheriou, Isabelle, Deray, Gilbert, Rixe, Olivier

Get full text

Phase I study combining PARP-inhibition with immune checkpoint blockade in women with BRCA-deficient recurrent ovarian cancer by Adams, S.F, Rixe, O, McCance, D, Lee, J.H, Eberhardt, S, Westgate, S, Rutledge, T, Muller, C

Get full text

514 Results of Phase 1b trial of the Indoleamine 2,3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma by Zakharia, Y, Drabick, J, Khleif, S, Munn, D, Link, C, Vahanian, N, Kennedy, E, Rixe, O, Milhem, M

Get full text

Gemcitabine-induced thrombotic microangiopathy: a systematic review by Izzedine, Hassane, Isnard-Bagnis, Corinne, Launay-Vacher, Vincent, Mercadal, Lucille, Tostivint, Isabelle, Rixe, Olivier, Brocheriou, Isabelle, Bourry, Edward, Karie, Svetlana, Saeb, Samir, Casimir, Nadine, Billemont, Bertrand, Deray, Gilbert

Get full text

Interstitial nephritis in a patient taking sorafenib by Izzedine, Hassane, Brocheriou, Isabelle, Rixe, Olivier, Deray, Gilbert

Get full text

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma by Zelek, Laurent, Barthier, S., Riofrio, M., Fizazi, K., Rixe, O., Delord, J. P., Le Cesne, A., Spielmann, M.

“…BACKGROUND Currently, there is no gold standard for the treatment of patients with metastatic breast carcinoma who have experienced failure with anthracyclines…”
Get full text

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study by Roy, A, Cunningham, D, Hawkins, R, Sörbye, H, Adenis, A, Barcelo, J-R, Lopez-Vivanco, G, Adler, G, Canon, J-L, Lofts, F, Castanon, C, Fonseca, E, Rixe, O, Aparicio, J, Cassinello, J, Nicolson, M, Mousseau, M, Schalhorn, A, D'Hondt, L, Kerger, J, Hossfeld, D K, Garcia Giron, C, Rodriguez, R, Schoffski, P, Misset, J-L

“…Background: Docetaxel and irinotecan chemotherapy have shown good efficacy in the treatment of advanced oesophago-gastric cancer. This randomised phase II…”
Get full text

A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer by Paridaens, R., Rixe, O., Pinel, M. C., Wildiers, H., Zorza, G., Ferré, P., Roche, H.

“…Objective To determine the recommended dose (RD) of vinflunine in combination with trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive…”
Get full text

New challenges in kidney cancer therapy: sunitinib by Izzedine, H, Billemont, B, Thibault, F, Rixe, O

Get full text

Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma by RAYMOND, E, FABBRO, M, VERMILLET, L, ARMAND, J. P, BOIGE, V, RIXE, O, FRENAY, M, VASSAL, G, FAIVRE, S, SICARD, E, GERMA, C, RODIER, J. M

“…To assess the antitumour activity and safety profile of irinotecan and its pharmacokinetic interactions with anticonvulsants in patients with glioblastoma…”
Get full text

Review article: overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta‐analysis? by MATHURIN, P, RIXE, O, CARBONELL, N, BERNARD, B, CLUZEL, P, BELLIN, M.-F, KHAYAT, D, OPOLON, P, POYNARD, T

“…Background: Controversies surrounding medical treatment in patients with unresectable hepatocellular carcinoma continue to persist. Aim: To perform a…”
Get full text

New therapeutics strategies in renal cell carcinoma by Meric, J-B, Billemont, B, Rixe, O

“…New medical strategies have emerged over the past decade for the treatment of advanced renal cell carcinoma based on the discovery of specific molecular…”
Get more information

Initial management in oncology: results of CPRIM surveys on 2,583 patient's perceptions and expectations (outside Anticancer Centers) by Ganem, G, Krakowski, I, Rixe, O, Batt, M, Brocvielle, A L

“…During the initial phase of management, the caregivers' role is particularly difficult. These two consecutive surveys have been conducted to cover three main…”
Get more information

Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients by Cals, L., Rixe, O., François, E., Favre, R., Merad, L., Deplanque, G., Laadem, A., Juin, P., Bereder, J. M., Bernardini, D., Herait, P.

“…Purpose: To determine maximum tolerated dose, safety and efficacy of weekly 24 h infusional 5-fluorouracil (5-FU) combined alternately with oxaliplatin and…”
Get full text